Adagio Medical Holdings Inc (ADGM) Dividendos

Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 86 full-time employees. The company went IPO on 2021-02-26. The company is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. The company is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.